CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 170 filers reported holding CLOVIS ONCOLOGY INC in Q4 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $667,000 | -20.6% | 560,565 | +20.1% | 0.00% | – |
| Q2 2022 | $840,000 | -10.8% | 466,652 | 0.0% | 0.00% | – |
| Q1 2022 | $942,000 | -19.9% | 466,652 | +7.5% | 0.00% | – |
| Q4 2021 | $1,176,000 | +278.1% | 433,983 | +1355.7% | 0.00% | – |
| Q4 2019 | $311,000 | +63.7% | 29,812 | -38.5% | 0.00% | – |
| Q3 2019 | $190,000 | -80.1% | 48,482 | -24.5% | 0.00% | – |
| Q2 2019 | $955,000 | +112.7% | 64,218 | +254.9% | 0.00% | – |
| Q1 2019 | $449,000 | -16.1% | 18,095 | -0.7% | 0.00% | – |
| Q3 2018 | $535,000 | -66.1% | 18,215 | -39.1% | 0.00% | – |
| Q1 2018 | $1,579,000 | +241.8% | 29,911 | +9103.4% | 0.00% | – |
| Q4 2017 | $462,000 | -99.5% | 325 | -100.0% | 0.00% | -100.0% |
| Q1 2017 | $84,788,000 | +14594.6% | 1,331,669 | +10143.6% | 0.02% | – |
| Q4 2016 | $577,000 | -91.6% | 13,000 | -93.2% | 0.00% | -100.0% |
| Q3 2016 | $6,890,000 | – | 191,122 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |